Natamycin

CAS No:
7681-93-8 Categories: , ,
  • #LGM Pharma is a Natamycin CAS# 7681-93-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 7681-93-8
  • AHFC code:
  • Synonyms:
  • ATC Code: A01AB10 A07AA03 D01AA02 G01AA02 S01AA10
  • Chemical Formula: C19H17NO7
  • Molecular Weight: 665.7252
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00826 (APRD01136)
  • SMILES: C[C,H]1OC(O[C,,H]2C[C,,H]3O[C,,](O)(C[C,H](O)[C,H]3C(O)=O)C[C,,H](O)C[C,H]3O[C,,H]3C=CC(=O)O[C,H](C)CC=CC=CC=CC=C2)[C,,H](O)[C,,H](N)[C,,H]1O
  • InChl: NCXMLFZGDNKEPB-BQGNJOPGSA-N
  • PubChem: 441382
  • IUPAC: (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-{[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0^{5,7}]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

Additional Details

Indication:
For the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis.
Pharmacodynamics:
Natamycin is an antifungal drug for topical ophthalmic administration. It is a tetraene polyene antibiotic derived from Streptomyces natalensis. It possesses in vitro activity against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusarium and Penicillium. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective in vitro against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid.
Mode of Action:
LIke other polyene antibiotics, Natamycin inhibits fungal growth by binding to sterols. Specifically, Natamycin binds to ergosterol in the plasma membrane, preventing ergosterol-dependent fusion of vacuoles, as well as membrane fusion and fission. This differs from the mechanism of most other polyene antibiotics, which tend to work by altering fungal membrane permeability instead.
Metabolism:
Toxicity:
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos